Toyocamycin, RNA self cleavage inhibitor; antitumor activity (TBI2750)
$126.00 – $450.00
RNA self cleavage inhibitor; antitumor activity
SKU | Stock | SIZE (mg) | Price | Quantity | ||
---|---|---|---|---|---|---|
TBI2750-5MG | Yes | 5 MG | $126.00 | |||
TBI2750-25MG | Yes | 25 MG | $450.00 |
- Description
- Terms
- Additional information
- Documents
- Reviews (0)
Description
Product Details
Formal Name: 4-Amino-7-β-D-ribofuranosyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile
Alternate Names: 7-Deaza-7-cyanoadenosine; NSC 63701; NSC 99843; Neuro 000027; Unamycin B; Vengicide
Molecular Formula: C12H13N5O4
Formula Weight: 291.26
CAS Number: 606-58-6
Purity: >98%
Formulation: powder
Solubility: Soluble in DMSO (up to 25 mg/ml)
Storage: -20°C
Stability: ≥ 1 year.
Applications
RNA self cleavage inhibitor; antitumor activity
Functions
An adenosine analog which inhibits ribozyme self cleavage in mammalian cells, EC50 = 0.4 µM (for expression of a luciferase reporter). A potent inhibitor of ER stress-induced XBP1 mRNA splicing. It suppresses thapsigargin-, tunicamycin- and 2-deoxyglucose-induced XBP1 mRNA splicing in HeLa cells without affecting ATF6 and PERK activation. Although unable to inhibit IRE1α phosphorylation, it prevented IRE1α-induced XBP1 mRNA cleavage in vitro. It inhibits not only ER stress-induced but also constitutive activation of XBP1 expression in multiple myeloma cell lines as well as in primary patient samples. Displays synergistic effects with bortezomib. Inhibits unfolded protein response and induces apoptosis in pancreatic cancer cells.
Application Procedures
First dissolved in DMSO (up to 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.
Additional information
SIZE (mg) | 25 MG, 5 MG |
---|
Be the first to review “Toyocamycin, RNA self cleavage inhibitor; antitumor activity (TBI2750)”
You must be logged in to post a review.
Reviews
There are no reviews yet.